Bleeding reports in people who have received the AstraZeneca COVID-19 vaccine and rare cases of thrombosis in relation to Johnson & Johnson vaccine reviewed by the European Medicines Agency.
While the Anglo-Swedish pharmaceutical company AstraZeneca is at the center of an upheaval for a possible link to rare cases of blood clots in the brain and abdomen, with consequent restriction of the use of its vaccine, this is an official revelation for research by J&J.
Four severe cases of rare low platelet thrombosis, one of which resulted in death, have been reported after vaccination with the J&J vaccine from the Janssen plant, said European Medicines Agency (EMA), as broadcast by Reuters and rebroadcast by the Athenian News Agency.
The agency said five cases of capillary leakage syndrome associated with AstraZeneca vaccine. This syndrome, in which blood flows from these tiny blood vessels to the muscles and body cavities, is characterized by swelling and a drop in blood pressure.
However, Coreper has said that “at this stage, it is not yet clear if there is a causal link” between vaccines and these incidents.
AstraZeneca and US-based J&J have not yet responded to requests for comment.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
